Pregnancy-associated breast cancers (PABCs) are tumors diagnosed during pregnancy or up to 5 years following parturition, and are usually high-grade, connective tissue-rich, and estrogen receptor (ER)/progesterone receptor-negative. Little is known about the cellular origin of PABCs or the mechanisms by which PABCs are initiated. Using the RCAS retrovirus to deliver the ErbB2 oncogene into the mammary epithelium of our previously reported MMTV-tva transgenic mice, we detected high-grade, poorly differentiated, stroma-rich and ER-negative tumors during pregnancy and lactation. These high-grade and stroma-rich tumors were less frequent in involuted mice or in age-matched nulliparous mice. More importantly, by generating a WAP-tva transgenic line for expression of ErbB2 selectively in WAP þ mammary alveolar cells, we found that tumors had similar morphological phenotypes (high grade, poorly differentiated, stroma-rich and ER-negative), irrespective of the time since pregnancy and even in the absence of pregnancy. These data suggest that PABCs arise preferentially from an alveolar cell population that expands during pregnancy and lactation. This somatic mouse model may also be useful for preclinical testing of new prophylactic and therapeutic strategies against PABC.
INTRODUCTION
Breast cancer arising either during pregnancy or up to 5 years postpartum is defined as pregnancy-associated breast cancer (PABC). 1 PABCs form a subtype of breast cancer characterized by increased tumor grade, Ki67 positivity, invasiveness, stromal involvement, estrogen receptor (ER)/progesterone receptor (PR) negativity, HER2 overexpression and poor prognosis. [2] [3] [4] Over the last few decades there has been a gradual but consistent increase in the incidence of PABCs globally and correspondingly, in the number of PABC-associated deaths. 5 It is, therefore, increasingly important to understand the mechanisms by which PABCs arise to identify novel risk factors and biomarkers, as well as more effective therapeutic and prophylactic strategies.
Xenograft studies in animal models have suggested that stromal accumulation during post-lactational involution in the breast is chiefly responsible for the poor prognosis associated with PABCs in humans. 6, 7 A tumor-promoting stromal milieu associated with involution has been reported to underlie the especially aggressive nature of PABCs diagnosed after parturition but within 2 years postpartum. [8] [9] [10] Moreover, the use of non-steroidal antiinflammatory drugs (NSAIDs) to circumvent this stromal recruitment during involution is able to ameliorate the increased metastatic potential of PABCs in rats. 11 Immature macrophages that accumulate in the breast during involution have also been reported to generate a pro-tumorigenic microenvironment promoting PABC growth. 8 The adult mammary gland has a well-organized cellular hierarchy that constitutes a ductal tree branching out from a main duct leading up to the nipple. Each duct in the ductal tree is comprised of two layers of cells: luminal epithelial cells that line the lumens of ducts, and basal (myoepithelial) cells that surround the luminal cells. 12 Most ducts end in alveoli, and their luminal cells (also called alveolar epithelial cells) usually produce whey acidic protein (WAP) and casein. 13 Alveoli proliferate rapidly during pregnancy as a result of stimulation by several growth factors and hormonal pathways that activate STAT5 and STAT6, 14, 15 and become highly secretory by late pregnancy and lactation. 16 Scattered in these basal and luminal layers are various compartmental progenitors. These different cell populations can transform into tumors representing different histopathological subtypes of human breast cancer. [17] [18] [19] [20] [21] Besides impacting histopathological feature, the cell of origin of breast cancer also significantly influences cellular composition, gene expression profile and cancer progression. 17, 18, 22 Here we report the surprising finding that the characteristics of PABC may also be encoded in a distinct subset of mammary cells from which the tumor originates.
RESULTS

ErbB2-induced PABCs in MMTV-tva mice grow rapidly and are aggressive
To study the contribution of the cell of origin on PABC phenotype, we used the RCAS-TVA mouse model system that allows an oncogene cloned into the RCAS retroviral vector to be delivered into a selected population of mammary epithelial cells (o0.3% of the mammary gland), more closely replicating human breast cancer initiation from a single cell in contrast to conventional genetically engineered mouse models. 23 This virus is derived from avian leukosis virus subgroup A, and mammary cells are made susceptible to RCAS infection using a mammary-selective promoter such as MMTV to drive transgenic expression of tva, which encodes the RCAS receptor. 24 While the MMTV promoter is responsive to ovarian hormones, baseline TVA protein levels in this transgenic line are easily detected and are not significantly altered during estrus (Supplementary Figure S1a) . As soon as the RCAS integrates into the host genome, any gene cloned in this retroviral vector is completely under the control of RCAS LTR, which is constitutively active but not hormonally influenced. 25 We used RCAS expressing a constitutively activated version of rat ErbB2 (HER2/Neu), RCAS-caErbB2, to initiate tumorigenesis because human HER2 amplification/overexpression has been associated with PABCs 26 , and, the ERBB2 protein activates an oncogenic pathway commonly activated in human breast cancer. 27, 28 We have reported that intraductal injection of RCAS-caErbB2 into MMTV-tva mice results in tumors with a median latency of B6 months. 23, 25 To demonstrate that we could induce PABCs, we injected 6-week-old MMTV-tva mice intraductally with RCAScaErbB2, mated half of the injected mice 4-7 days later, and palpated both cohorts of virgin control and mated mice for signs of tumor. A subpopulation of the parous cohort developed tumors during lactation and the first 4 days of involution (Figure 1a ). These tumors were collectively termed mouse PABCs (mPABCs), as they conformed to the most rigorous definition of postpartum human PABCs (hPABCs) by arising during lactation and early involution. More than half of the mice in the parous cohort (12/22) developed mPABCs, whereas only 1 out of 17 (5.9%) virgin control mice developed a tumor during the same time frame (P ¼ 0.003; Figure 1a ). Parous mice that developed tumors 450 days after parturition (after 1 month of involution) constituted the 'Late onset parous' (PLO) group. This cohort along with virgin mice that developed tumors formed two control groups to which PABC tumor phenotypes were compared (Figure 1a ). Of note, the decreased tumor latency in the mPABC group was unrelated to a pregnancy-associated increase in oncogene expression, a common concern with conventional transgenic models. The caErbB2 protein level, as measured by the HA tag, was confirmed to be similar in tumors from all three cohorts (Supplementary Figures  S1b and c) , as predicted from the ubiquitous nature of the RCAS LTR.
Similar to the high-grade phenotype of hPABCs, mPABCs had a fourfold increase in growth rate compared with 'Late onset tumors' in parous mice (Figure 1b) . In further concordance with hPABCs, mPABCs had a threefold higher Ki67 index than 'Late Figure 1 . PABC arises in MMTV-tva mice intraductally injected with RCAS-caErbB2. (a) Dot plot showing that PABCs (red) arose during lactation and the first 4 days of involution (p25 days after parturition), whereas 'Late onset tumors' in parous mice arose more than 1 month after weaning (white) and tumors in virgin mice predominantly arose X80 days after intraductal injection of RCAS-caErbB2 (comparable to X50 days postpartum) (black). Boxes denote the tumors included in each parous group. (b) Box plot showing tumor growth rate for all tumors calculated as number of weeks required for tumors detected at 0.5 cm diameter to reach 1.8 cm at euthanasia. Tumor diameter was measured using calipers twice weekly. Figure 1c) . The higher proliferation of mPABC cells was also reflected in a 2.5-fold increase in the number of mitotic cells relative to 'Late onset tumors' in parous mice (Figure 1d ). Apoptosis, as detected both by TUNEL and cleaved caspase 3 (CC3) levels, was not affected by pregnancy and remained comparable between mPABCs and 'Late onset tumors' in parous mice (Figures 1e and f) . Tumor histology in all three cohorts (virgin, PLO and mPABC) was complex. Each individual tumor had two or more distinctive histopathological subtypes, including well-and poorly differentiated adenocarcinomas, adenosquamous and squamous carcinomas, and epithelialmesenchymal-transition (EMT)-type tumors (examples are shown in Supplementary Figure S1d) . The relative area of the total tumor occupied by the poorly differentiated histological subtypes was greater in the mPABCs than in either 'Late onset tumors' from parous mice or tumors from virgin animals (P ¼ 0.02; Figure 2a ). Adenosquamous carcinoma was particularly prominent in the mPABC group. The peripheries of these squamous-differentiated tumors were aggressively invasive, with highly pleomorphic cells permeating into the surrounding tissues. Like hPABCs, mPABCs had increased collagen deposition (indicating a significant increase in stromal involvement, as measured by trichrome stains) relative to the 'Late onset tumors' in parous mice and virgin mice (Figure 2b ). Finally, similar to hPABCs, mPABCs were predominantly ER-negative, as were the 'Late onset tumors' in parous animals and virgin animals ( Figure 4a ).
Of note, the intratumor heterogeneity in these tumors is not likely to be due to a polyclonal origin-in most tumors, latency was several months (Figure 1 ), indicating the need for a rarely occurring spontaneous secondary somatic mutation. This requirement lowers the chance of two or more neighboring infected cells gaining a key secondary mutation at a similar time point and then co-evolving into an overt tumor. Accordingly, using FISH to detect the RCAS provirus, we found that, although morphologically variable, seven of the nine tumors analyzed were homogeneous for either one or two integration sites, suggesting that they likely evolved from a single infected cell (though we could not exclude the possibility that some of them might have arisen from two neighboring cells that were both infected by the same number of viral particles). Two tumors comprised cells with variable integration events, suggesting that they were oligoclonal (Supplementary Figure S1e) . Therefore, the great majority of tumors had a monoclonal cell of origin but later become oligoclonal in cellular differentiation as evidenced by intratumor histopathological heterogeneity.
ErbB2-induced PABCs have intratumor cellular heterogeneity including cells with alveolar markers Next, cell lineage markers were used to confirm both the intraand inter-tumor cellular heterogeneity indicated by the above histopathological studies. Both the well-and poorly differentiated adenocarcinoma in all three groups were comprised of predominantly cytokeratin 8 (K8, a luminal cell marker)-positive cells and only a few cytokeratin 5-positive (K5 þ ) basal cells ( Figure 3 ). The regions of squamous cell carcinoma in every tumor mass were uniformly positive for K5 and weakly positive for K8, whereas the EMT-type tumor cells in every group stained for both vimentin and K8 and had occasional K5 þ cells (not shown). More importantly, the mPABCs had significantly higher percentages of 
predominantly K8
þ (Figures 3b and e) . K5 þ cells in the mPABCs were largely HA þ (Figures 3c and f), indicating that they were progeny of cells infected by RCAS-caErbB2 and were not normal mammary cells entrapped within the tumor. This indicates that the cell of origin is pluripotential, with inherent plasticity, and the ability to undergo metaplastic changes from luminal cells (typically columnar) to squamous epithelium. In contrast, the few cells that were K5 þ in the 'Late onset tumors' of parous mice and tumors in virgin mice were predominantly HA À and well organized, indicating that these cells were part of the normal mammary myoepithelium entrapped in tumors (Figures 3c and f ). These differences in cellular heterogeneity suggest that PABCs may have a different cell of origin-possibly a bipotential progenitor-from the 'Late onset tumors' in these parous mice.
We also found a 43-fold enrichment for two traditional alveolar markers, phosphorylated signal transducer and activator of transcription 5 (pSTAT5) and WAP 13, 29, 30 in mPABCs relative to 'Late onset tumors' in parous mice and tumors in virgin mice (Figures 4b-d) . The enrichment of alveolar markers in mPABCs suggests that these tumors potentially originate from an alveolar cell. Together, these observations suggest that mPABCs constitute a tumor subtype that is distinct from 'Late onset tumors' in parous mice as well as those in virgin mice, possesses hPABC tumor characteristics (rapid growth, high grade, poor differentiation and stroma involvement), and may originate from alveolar cells possessing the potential to differentiate into both K8 þ and K5 þ lineages upon oncogene activation.
WAP-tva transgenic mice enable selective expression of oncogene in alveolar cells
To test whether PABC phenotypes could indeed be recapitulated by alveolar cells undergoing transformation, we targeted caErbB2 selectively into the alveolar cell population. WAP is an integral component of breast milk and is generally restricted to cells of the alveolar lineage. 13 WAP expression, in accordance with its function, remains at baseline levels in the nulliparous mammary gland where it is regulated by the estrus cycle, and is maximal during pregnancy and lactation. 13 Therefore, we generated a transgenic mouse line transcribing the gene encoding the TVA receptor from the promoter of WAP (Figure 5a ). In virgin WAP-tva mice, the TVA protein level of individual mammary cells varied within the estrous cycle (Supplementary Figure S2a) , as expected of this hormone-responsive promoter. Based on flow cytometry analysis of single-cell suspensions of mammary cells that were stained for TVA, 13.6±3.7% of cells were TVA þ in MMTV-tva mice (n ¼ 18), but the TVA þ cell proportion dropped to 9.9±4.6% in WAP-tva mice (n ¼ 21; P ¼ 0.007), consistent with a restricted population of cells expressing WAP in the mammary gland compared with the broader cell population that is responsive to the MMTV promoter. Importantly, based on qPCR, TVA þ cells were enriched for WAP mRNA48-fold (P ¼ 0.015) relative to TVA À /Lin À cells, demonstrating the specificity of tva expression in WAPexpressing cells (Figure 5c ). During pregnancy and lactation, as the alveoli increased in number and upregulated WAP, the TVA protein increased in intensity and could be detected on the membrane of many more cells (Figure 5b ). Together, these data indicate that similar to endogenous WAP, TVA in the WAP-tva mice is restricted to cells from an alveolar lineage in the mouse mammary gland.
To further characterize the TVA þ cell population in this new WAP-tva mouse line, we used flow cytometry to analyze the mammary cell lineage markers, CD24 and CD49f. Mouse mammary luminal progenitor cells are enriched in the CD24 hi / CD49f lo mammary colony-forming cell (Ma-CFC) population. 31 The Ma-CFC fraction was almost threefold larger in the TVA þ cell population in the WAP-tva line than in the MMTV-tva line (Figures  5d and e) . This result suggests that TVA þ cells in WAP-tva mice, while being alveolar, are enriched for cells with progenitor potential relative to TVA þ cells in MMTV-tva mice. In accord with this inference, in an in vitro colony-forming assay, the TVA þ cell population from the WAP-tva line formed significantly more colonies than TVA þ cells from MMTV-tva mice (Figures 5f and g ).
An alveolar cell of origin leads to rapidly growing, high-grade, poorly differentiated PABC-like tumors regardless of time since pregnancy or even in the absence of a pregnancy in WAP-tva mice Having established a mouse line where oncogenic signaling could be targeted to a luminal cell population largely restricted to the alveolar lineage, we tested whether tumors generated from these cells preferentially formed a PABC-like tumor subtype. We first determined the infection rate to be B0.3% of the mammary epithelial cells based on intraductal injection of 1 Â 10 7 IUs of the RCAS-GFP reporter virus per gland into 12-week-old WAP-tva virgin mice (Supplementary Figure S2b) . This rate is similar to what is observed in MMTV-tva mice, despite the higher frequency of TVA þ cells in MMTV-tva mice (Supplementary Figure S2b) . Then, we injected WAP-tva mice with the RCAS-caErbB2 virus, and 4-7 days later allowed half the mice to undergo a full-term pregnancy and 3 weeks of lactation while maintaining the other half as virgin controls. As in the MMTV-tva mice, we detected mPABCs that arose during lactation and the first week of involution, but also detected an early onset subgroup of tumors that arose with comparable latency in the virgin mice (P ¼ 0.99; Figure 6a ). We confirmed that the ErbB2 protein level was unperturbed by pregnancy/lactation hormones in mPABCs from WAP-tva mice (Supplementary Figure S2c) . We also validated that the caErbB2 protein level in tumors was comparable between MMTV-tva and WAP-tva mice regardless of parity or time at detection (Supplementary Figure S3) . mPABCs and 'Late onset tumors' in the WAP-tva parous mice grew at a similar rate, which was comparable to the rapid growth rate of mPABCs in the MMTV-tva mice (Figure 6b ). Ki67 positivity was similarly high in mPABCs and 'Late onset tumors' from parous WAP-tva mice as well as from virgin WAP-tva mice (Figure 6c) . Also, comparable numbers of tumor cells were in mitosis (Figure 6d ) and there was no observable difference in apoptosis (Figures 6e and f) . Therefore, both PABCs and 'Late onset tumors' in parous WAP-tva mice grow equally fast with similarly high levels of cellular proliferation. These data suggest that the recency of a pregnancy does not affect growth or proliferation of tumors arising from an alveolar cell population, unlike in the MMTV-tva line.
All three groups of WAP-tva tumors (mPABC, 'late onset parous' mice and virgin mice) also contained complex histopathological subtypes including squamous cell carcinomas, poorly differentiated adenocarcinomas and EMT-like tumors, but they resembled mPABCs in MMTV-tva mice more than the other tumor subsets in MMTV-tva mice (Figure 7a ). Stromal involvement was extensive in all three tumor groups of WAP-tva mice, as in mPABCs in the MMTV-tva mice (Figure 7b ). Moreover, all three groups had significant K5 positivity, comparable to the level in mPABCs from MMTV-tva mice and much higher than the level in 'Late onset tumors' from the MMTV-tva mice (Figures 8a and d) . Again, the K5 þ cells also contained the HA tag of the RCAS-caErbB2 provirus (Figures 8b and e) , indicating that these cells originated from the initial virus-infected cell population and were not normal myoepithelial cells recruited to the tumor. Corresponding to the higher K5 þ tumor cell number, tumors from all three groups of WAP-tva mice had lower numbers of K8 þ cells than 'Late onset tumors' from the parous MMTV-tva mice (Figures 8c and f) . These data also suggest that luminal cells in WAP-tva mice can produce additional cell lineages under oncogenic stress even though they normally give rise to only the luminal cell population in an intact mammary gland. As with the MMTV-tva mice, all three groups of tumors in WAP-tva mice were largely ER-negative (Figure 9a ). Tumors from WAP-tva virgin mice were more likely to be ER-negative than those from virgin MMTV-tva mice (P ¼ 0.001; Figure 9b ), indicating that ER status is also influenced by the tumor cell of origin. Taken together, these results suggest that an alveolar cell of origin can predispose to a tumor with high grade, poor differentiation and increased stromal involvement, irrespective of the time since pregnancy and even in the absence of pregnancy.
DISCUSSION
Our study is the first to report an impact of cell of origin on PABC phenotype and our results indicate that the cellular origin of the tumor is a critical contributing factor to the reported characteristics of PABCs. While 'Late onset tumors' in parous MMTV-tva mice lacked PABC characteristics including rapid growth, high proliferation, high metaplastic change and collagen deposition, tumors from parous WAP-tva mice, irrespective of the time since pregnancy, had these PABC characteristics (Figures 7 and 8) . As the 'Late onset tumors' in these parous WAP-tva mice are no longer exposed to stroma associated with active involution, our data indicate that an alveolar cell of origin can predispose to PABC long after the pregnancy/involution stimuli have disappeared. In support of this interpretation, tumors arising in nulliparous mice of the WAP-tva line exhibited characteristics of hPABCs and were similar to both mPABC and 'Late onset tumors' in WAP-tva parous mice.
The phenotypic differences between PABCs and 'Late onset tumors' in parous mice of the MMTV-tva line are likely due to a difference in the cell of origin. In this transgenic line, tva expression, and therefore oncogene delivery, is not restricted to a specific subset of mammary cells but rather distributed to various subtypes of mammary cells; therefore tumors could arise from different subsets of RCAS-caErbB2-infected cells depending upon selective pressure and evolutionary advantage (such as a pregnancy). However, the microenvironment of pregnancy, lactation and involution may also modulate tumor phenotypes in this transgenic line, and may convert the phenotype of tumors arising from non-alveolar cells into phenotypes that bear the characteristics of PABC. Therefore, our results and data interpretation do not disprove previous reports regarding the impact of involuting stroma on phenotypes of PABC.
It is of interest to note that tumor cell proliferation and growth appeared dependent more on the cell of origin than on pregnancy association. Compared with 'Late onset tumors' in parous MMTV-tva mice and tumors in virgin mice, the Ki67 index and the number of cells entering mitosis were relatively high in the WAP-tva line irrespective of time since pregnancy or even in the absence of pregnancy (Figures 6c and d) . Similarly, time to tumor volume doubling was comparable among all three groups of WAP-tva tumors (Figure 6b) .
Our results may also have implications on the mechanisms by which pregnancy impacts breast cancer risk. Epidemiological studies indicate that pregnancy in young women protects against breast cancer. 33 Moreover, based on reduced mammary cell proliferation following a pregnancy in women and rodents, it has been postulated that pregnancy-induced protection against breast cancer occurs through the inhibition of proliferation. 34 Our observation that the growth of tumors originating from WAP þ cells is not affected by a pregnancy suggests that tumors as well as premalignant lesions arising from alveolar cells might be outside the protective effects of pregnancy. However, it remains to be tested whether alveolar cell tumorigenesis initiated by a different oncogene may still be modulated by a pregnancy.
The risk of PABCs appears to increase with a woman's age at pregnancy, 1 but the reasons are unclear. This age dependence might be due to the normal changes of breast epithelia and/or stroma during ageing; however, it is also possible that pre-existent oncogenic insults (such as HER2 amplification) in the breast epithelium might appear with greater likelihood in older women. [35] [36] [37] These pre-existent insults may be preferentially responsive to the potent hormonal milieu induced by pregnancy and lactation, and therefore may be able to form tumors more rapidly under these stimuli. It is also possible that with pregnancy, mammary cells with oncogenic mutations in an ageing breast might be more readily forced into an alveolar lineage, which might evolve into tumors more rapidly. There are few animal models that can recapitulate PABC initiation, and previous models largely utilize xenograft tissue. 7 The RCAS-TVA mouse model system appears to comprehensively recapitulate the PABC phenotype, and the use of this somatic model system may help uncover the molecular and cellular mechanisms by which PABCs arise and progress.
The cell of origin has been reported to affect breast tumor ER status, 20, 38 and the results of our study further support this connection. The preponderance of ER-negative PABC tumors has been suggested as a contributory factor to poor prognosis and survival of PABC patients. In fact, several epidemiological studies suggest that the tumor subtype associated with PABCs, rather than the pregnancy itself, is responsible for the poor prognosis of PABCs. 39 Our data support this epidemiological observation, as the alveolar cell of origin in itself predicates an ER-negative breast cancer even in the absence of a pregnancy (Figure 9b) .
PABCs, being largely ER À and advanced at diagnosis, are difficult to treat. It is therefore crucial to identify new molecular targets for therapeutic and prophylactic strategies. The identification of a potentially distinct alveolar progenitor cell of origin for PABCs suggests that proteins regulating alveolar differentiation, such as Prl-PrLR-Jak2-pSTAT5 signaling, might be important as targets for intervention strategies. Moreover, the identification of an alveolar gene expression signature or protein biomarker that can be estimated non-invasively might be valuable for predicting women at higher risk of being diagnosed with postpartum PABC. In addition, our mouse model may also be valuable for preclinical testing of therapeutics that may be especially potent against PABC.
Taken together, the results of our study identify for the first time the critical effects of cell of tumor origin on PABC characteristics. Using a mouse model well suited for studying tumor formation in vivo, we recapitulated the properties of PABCs as distinct from those of 'Late onset tumors' in parous mice. Furthermore, we showed that tumor origination in alveolar cells significantly increased PABC characteristics irrespective of time since pregnancy and even parity per se. Translationally, it may be illuminating to investigate whether human PABCs are associated with alveolar markers, pSTAT5 levels or metaplasia. Identification of an alveolar progenitor signature in human PABCs might provide therapeutic targets, as well as prophylactic strategies. Most importantly, identification of key dysregulated molecular pathways contributing to PABC initiation in humans may be valuable for the identification of risk factors and biomarkers, facilitating early detection of PABCs.
MATERIALS AND METHODS
Experimental animals
MMTV-tva (MA) mice in a FVB genetic background used in these studies have been previously reported. 23 All animals were euthanized according to the National Institutes of Health guidelines. The animal protocol was approved by the Institutional Animal Care and Use Committees of Baylor College of Medicine, Houston, TX, USA. The WAP-tva transgenic vector was constructed in pBS-WAP, which contains the 7.3-kb WAP gene. 40 TVA was removed from pSP72(0.8) 41 using Asp718 and EcoRI (Klenow) and inserted into Asp718 and SalI (Klenow) sites in pBS-WAP (a gift of Dr Lothar Hennighaussen), thus resulting in removal of the WAP gene between exon 1 and exon 3, respectively. The resulting transgenic construct contains the WAP promoter, the quail tva cDNA (850 bp) encoding a glycosyl- phosphatidylinositol-linked form of TVA, and the WAP poly-A signal. This 6.4-kb transgene fragment was removed from the transgenic vector by digestion with EcoRI and injected into pronuclei from FVB/N mice. Candidate founders were screened by PCR using primers specific to tva. MMTV-tva mice have been previously described. 23 Virus preparation and delivery RCAS virus was prepared as described earlier. 23 The lentiviral vector (FC-CGW) carrying either GFP alone or both GFP and caErbB2 was prepared as described earlier. 42 Tumor studies Four-seven days after intraductal injection of RCAS, the experimental group consisting of approximately half the mice was mated. Pups were weaned at lactation day 21. All mice were palpated thrice-weekly for tumor incidence. Tumor-free mice were euthanized 12 months post injection. Tumor growth rate was calculated based on two diametric measurements taken at initial detection (diameterp0.5 cm) and at time of euthanasia (diameter ¼ 1.8 cm) and the intervening time interval.
FISH analysis
FISH was performed to identify the copy number or integration sites for the RCAS retrovirus on paraffin sections from MMTV-tva mPABC and virgin tumors. The plasmid clone containing RCAS sequences was labeled by nick translation with Spectrum Red (Abbott Laboratories, Des Plaines, IL, USA). Hybridization and detection were performed according to the manufacturer's protocols. The slides were counterstained with 4 0 , 6-diamidino-2-phenylindole (DAPI) and the images were captured using Nikon E800 microscope (Melville, NY, USA) equipped with a cooled-charge coupled devices (CCD) camera. The cells were analyzed using Quips Pathvysion (Applied Imaging, Santa Clara, CA, USA). A total of 50 interphase nuclei per sample were analyzed for the number of integration events.
Single-cell suspension preparation from mammary glands and quantitative reverse transcription PCR.
Mammary glands were collected with removal of lymph nodes. Single-cell suspensions were prepared as previously described. 31 For quantitative reverse transcription PCR of WAP and tva expression, single-cell suspensions were prepared from mammary glands, and cells were stained using antibodies against CD45, CD31 and Ter119 (Lin) and TVA. Using FACS, TVA þ and TVA À /Lin À cells were sorted out, RNA was isolated and reverse transcription was performed to generate cDNA.
Flow cytometry analysis and FACS
Flow cytometry analysis was performed on a BD LSRII (BD Bioscience, San Jose, CA, USA). FACS was performed on an AriaI w/ UV (BD Bioscience) with a 130-mm nozzle. Antibodies used for flow cytometry include a PEconjugated rat antibody against CD24 (553262, BD Bioscience), PEconjugated rat IgG2b k isotype (553989, BD Bioscience), FITC-conjugated rat anti-CD49f (555735, BD Bioscience) and FITC-conjugated rat IG2b k isotype (553988, BD Bioscience). A rabbit polyclonal antibody against TVA (gift from Andy Leavitt) and an APC-conjugated goat anti-rabbit IgG (A10931, Invitrogen, Carlsbad, CA, USA) were used. Dead cells were gated out based on propidium iodide positivity.
Colony-forming assay
Mammary glands from virgin MMTV-tva and WAP-tva mice were digested as described above and FACS was performed to sort out TVA þ cells. A total of 1000 TVA þ cells from each mouse was plated in triplicate on reduced growth factor Matrigel (354230, BD Bioscience) on plastic with DMEM/F12 medium supplemented with 20 ml/ml B27 (17 504-044; Invitrogen), 20 ng/ml bFGF (13 256-029; Invitrogen), 20 ng/ml EGF (13 247-051; Invitrogen), antibiotic/antimycotic (15240-062; Invitrogen) and 5% Fetal Bovine Serum. One week after plating, colonies (X50 mm) were quantified.
Tissue harvest
Tumors and mammary tissue were fixed in 4% paraformaldehyde overnight at 4 1C, paraffin-embedded and sliced into 3-mm sections. Sections were deparaffinized in xylene, rehydrated in graded alcohol, and used for histology and immunostaining.
Immunostaining and microscopy Immunohistochemistry (IHC) and immunofluorescence (IF) were performed as described earlier. 23 Antigen retrieval was carried out by heating sections in 10 mM sodium citrate, pH 6.0. MOM and VectaStain Elite ABC Rabbit kits (Vector Labs, Burlingame, CA, USA; cat. nos PK-2200 and PK-6101) were used according to manufacturer's protocols. Primary antibodies used included mouse monoclonal antibody against HA (Covance, Princeton, NJ, USA; 1:500); rabbit IgG specific for cleaved caspase 3 (Cell Signaling, Danvers, MA, USA; 1:200), K5 (1:200), ER (Santa Cruz Biotechonology, Santa Cruz, CA, USA; 1:200), pHistone3 (Millipore, Billerica, MA, USA; 1:200) and Ki67 (Novocastra, Buffalo Grove, IL, USA; 1:200); and rat IgG specific for K8 (1:200) . Incubation with the primary antibody for IF staining was overnight at 4 1C, whereas incubation with primary antibody for IHC was 1 h at room tempertaure. Nuclei were counterstained with DAPI-containing mounting medium and hematoxylin, respectively, for IF and IHC. Bright-field images were captured using a Leica DMLB microscope, and images were processed with Magnavision and Adobe Photoshop software. Fluorescent images were captured with a Zeiss Axiskop2 plus microscope (Zeiss, Thornwood, NY, USA). Images were processed with Axiovision and Adobe Photoshop software.
Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay Paraffin-embedded gland and tumor sections were treated in proteinase K and subjected to the terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay using the ApopTag Red in situ TUNEL detection kit (Chemicon, Temecula, CA, USA, S7165). Nuclei were counterstained with DAPI-containing mounting medium.
Trichrome staining
Trichrome staining was performed on paraffin-embedded sections using Accustain Trichrome Stain Kit (Sigma, St Louis, MO, USA catalog no. HT15), Bouin's solution (Sigma, catalog no. HT10132) and Weigert's Iron Hematoxylin Set (Sigma, catalog no. HT10-79). Sections were deparaffinized as for other immunohistochemical procedures and then treated as per manufacturer's instructions. Sections were allowed to clear in xylene overnight before being mounted.
Quantification of stained sections
Five random fields were viewed and a total of at least 5000 cells were counted per sample. Image J software was used for counting, and either DAPI or hematoxylin nuclear staining was used to identify the total number of cells. For tumor histopathological quantification, tumor sections were viewed microscopically and scored by the investigators and independently by a pathologist.
Statistical analysis
All numbers in the text were represented as mean ± s.e.m. Statistical analysis of quantification of stained sections was done using analysis of variance or Student's t-test for independent samples with Holm's correction for multiple comparisons when distribution of data was judged to be normal. Where distribution was not normal (assessed using Q-Q plots with the Wilk-Shapiro test of normality), either Kruskal-Wallis or Wilcoxon's Rank Sum test was used. Holm's correction was also used where required when using non-parametric tests. For categorical data with o15 data points in each group, the Fisher's exact test was used. For categorical data with X15 data points in each group, the Pearson's chi-square test was used. All graphs and statistical analyses were generated either in MS Excel or R.
